TABLE 4

Fatty acid composition in the livers of bezafibrate-treated wild-type (+/+) and Ppara-null (−/−) mice

Results are expressed as mean ± S.D. (n = 6 in each group).


Bezafibrate

Ppara(+/+)

Ppara(−/−)
0 mg/kg/day
10 mg/kg/day
100 mg/kg/day
0 mg/kg/day
10 mg/kg/day
100 mg/kg/day
C12:0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.1 ± 0.0
C14:0 0.8 ± 0.0 0.7 ± 0.1 0.7 ± 0.0 0.7 ± 0.0 0.6 ± 0.0 0.6 ± 0.2
C14:1 n-5 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
C16:0 27.6 ± 2.0 29.2 ± 4.0 28.0 ± 0.1 20.9 ± 0.3 23.6 ± 4.0 20.8 ± 0.2
C16:1 n-7 2.5 ± 0.4 2.0 ± 0.5 3.4 ± 1.1 2.0 ± 0.2 1.6 ± 0.1 2.0 ± 0.8
C18:0 12.6 ± 0.4 12.5 ± 2.0 11.1 ± 1.1 12.8 ± 0.3 14.0 ± 1.5 8.5 ± 0.3*
C18:1 n-9 11.9 ± 0.4 10.5 ± 3.4 15.6 ± 1.1* 13.9 ± 0.3 11.0 ± 3.0 18.4 ± 3.5
C18:2 n-6 21.9 ± 0.4 23.3 ± 3.7 15.9 ± 0.3* 25.8 ± 0.3 25.8 ± 1.8 27.6 ± 3.5
C18:3 n-6 0.2 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.2 ± 0.0*
C18:3 n-3 1.0 ± 0.1 0.7 ± 0.2 0.3 ± 0.1* 1.4 ± 0.2 0.7 ± 0.2 0.9 ± 0.1
C20:0 0.5 ± 0.2 0.4 ± 0.1 0.2 ± 0.0 0.7 ± 0.0 0.5 ± 0.2 0.5 ± 0.0
C20:1 n-9 0.7 ± 0.1 0.7 ± 0.4 0.6 ± 0.0 1.1 ± 0.0 0.9 ± 0.3 1.4 ± 0.2
C20:2 n-6 0.5 ± 0.0 0.5 ± 0.1 0.4 ± 0.0* 0.8 ± 0.1 0.7 ± 0.1 0.9 ± 0.1
C20:3 n-9 0.1 ± 0.0 0.1 ± 0.0 0.3 ± 0.1* 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
C20:3 n-6 2.0 ± 0.1 2.0 ± 0.1 4.0 ± 0.1* 1.6 ± 0.1 1.4 ± 0.1 1.4 ± 0.0
C20:4 n-6 6.2 ± 0.4 6.5 ± 0.5 7.4 ± 0.8 5.6 ± 0.1 6.7 ± 0.7 5.2 ± 0.4
C20:5 n-3 0.8 ± 0.2 0.8 ± 0.3 1.2 ± 0.3 1.1 ± 0.1 1.1 ± 0.1 1.0 ± 0.3
C22:0 0.1 ± 0.1 0.1 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 0.1 ± 0.0 0.1 ± 0.0
C22:1 n-9 0.2 ± 0.1 0.2 ± 0.0 0.1 ± 0.0 0.2 ± 0.0 0.2 ± 0.0 0.3 ± 0.1
C22:4 n-6 0.2 ± 0.0 0.3 ± 0.1 0.3 ± 0.0 0.3 ± 0.0 0.4 ± 0.1 0.6 ± 0.1*
C22:5 n-3 0.7 ± 0.2 0.7 ± 0.0 1.0 ± 0.2 1.1 ± 0.0 1.1 ± 0.2 1.2 ± 0.3
C22:6 n-3 9.0 ± 0.7 8.5 ± 1.9 9.1 ± 0.1 9.3 ± 0.2 8.9 ± 0.2 8.1 ± 0.3*
C24:0 0.0 ± 0.0 0.0 ± 0.0 0.0 ± 0.0 0.1 ± 0.0 0.0 ± 0.0 0.0 ± 0.0
C24:1 n-9
0.1 ± 0.0
0.1 ± 0.0
0.1 ± 0.0
0.1 ± 0.0
0.1 ± 0.0
0.1 ± 0.0
  • * P < 0.05, between treated and untreated mice of the same genotype.